Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1345 details
Primary information
ThPP IDTh1049
Therapeutic Peptide/Protein NameInterferon beta-1a
SequenceMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQF view full sequnce in fasta
Functional ClassificationIb
Molecular Weight20027
Chemical FormulaC908H1408N246O252S7
Isoelectric Point8.93
Hydrophobicity-0.427
Melting Point (℃)N.A.
Half Life10 hours
DescriptionHuman interferon beta (166 residues, glycosylated, MW=22.5kD) is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence of Avonex is identical to that of natural human interferon beta.
Indication/DiseaseFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
PharmacodynamicsInterferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.
Mechanism of ActionInterferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance33-55 L/hour [Healthy SC injection of 60 mcg]
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearnceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsIn injection site reactions, symptoms can include redness, swelling, discolouration, inflammation and pain. These may be reduced by the use of an auto-injector device.
Useful Linkhttp://www.netdoctor.co.uk/brain-and-nervous-system/medicines/betaferon.html
PubMed ID27835061, 27314959, 27126827, 27035896, 26384035, 26039748, 25941954, 25846320, 25666445
3-D StructureTh1049 (View) or (Download)